TASADENOTUREV
Neoplasm, Nerve Tissue
DNAtrix, Inc.gene_therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Neoplasm, Nerve Tissue cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Hoffmann-La Roche | Phase 3 | BB |
Carboplatin Blueprint Medicines Corporation | Phase 3 | BB |
Pralsetinib, trans- Hoffmann-La Roche | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Hoffmann-La Roche | Phase 3 | B |
Microbubble NaviFUS Corporation | Phase 3 | B |
View all 13 →
Same molecule, other indications
TASADENOTUREV is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →